1-20 of 102
Rebecca Garris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Sangeetha Venugopal, Hagop Kantarjian, Nicholas J. Short, Philip A. Thompson, Naveen Pemmaraju, Nitin Jain, William G. Wierda, Gautam Borthakur, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Jennifer Thankachan, Benjamin Nwakanme, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 1239.
DOI: https://doi.org/10.1182/blood-2021-153826
Published: 2021
Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Philip A. Thompson, Alessandra Ferrajoli, Tapan M. Kadia, Nitin Jain, Yesid Alvarado, Musa Yilmaz, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Steven M. Kornblau, Marina Konopleva, Guillermo Garcia-Manero, Rebecca Garris, Heather M Schroeder, Anna Milton, Juan Rivera, Glenda Banks, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 1233.
DOI: https://doi.org/10.1182/blood-2021-154022
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Fadi Haddad, Hagop Kantarjian, Nicholas J. Short, Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Koichi Takahashi, Naval Daver, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Jovitta Jacob, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3363.
DOI: https://doi.org/10.1182/blood-2021-154155
Published: 2021
Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, William G. Wierda, Steven M. Kornblau, Jovitta Jacob, Monica Kwari, Caitlin R. Rausch, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3400.
DOI: https://doi.org/10.1182/blood-2021-154074
Published: 2021
Journal Articles

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Marina Konopleva, Sai Prasad Prasad Desikan, Nitin Jain, Farhad Ravandi, Xuelin Huang, William G. Wierda, Gautam Borthakur, Koji Sasaki, Ghayas C. Issa, Yesid Alvarado, Naveen Pemmaraju, Guillermo Garcia-Manero, Courtney D. DiNardo, Jennifer Thankachan, Ricardo Delumpa, Anna Milton, Juan Rivera, Lourdes Waller, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 2298.
DOI: https://doi.org/10.1182/blood-2021-153795
Published: 2021
Journal Articles

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masarova, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Anna Milton, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 2299.
DOI: https://doi.org/10.1182/blood-2021-154124
Published: 2021
Journal Articles

A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Fadi Haddad, Hagop Kantarjian, Nicholas J. Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Naval Daver, Yesid Alvarado, Koichi Takahashi, Guillermo Garcia-Manero, Michelle Velasquez, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 4398.
DOI: https://doi.org/10.1182/blood-2021-149261
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
DOI: https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
DOI: https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
DOI: https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
DOI: https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
DOI: https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Yuya Sasaki, MDPhD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P Andrew Futreal, PhD, Feng Wang, PhD, Ken Furudate, DDM, PhD, Rebecca Garris, MSc, Koichi Takahashi, MD PhD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
DOI: https://doi.org/10.1182/blood-2020-136676
Published: 2020
Journal Articles

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD PhD, Steven M. Kornblau, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Partow Kebriaei, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Jairo A. Matthews, Munazza Noor, Rebecca Garris, MSc, Farhad Ravandi, MBBS, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
DOI: https://doi.org/10.1182/blood-2020-141971
Published: 2020
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
DOI: https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
DOI: https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
DOI: https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
DOI: https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kathryn G. Roberts, PhD, Koji Sasaki, MD, Yaqi Zhao, MSc, Chunxu Qu, PhD, Zhaohui Gu, PhD, Nitin Jain, MD, Keyur P. Patel, MBBS, PhD, Farhad Ravandi, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Rebecca Garris, MSc, Steven Kornblau, Marina Y Konopleva, MD PhD, Charles G. Mullighan, MBBS, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1641.
DOI: https://doi.org/10.1182/blood-2019-126940
Published: 2019
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
DOI: https://doi.org/10.1182/blood-2019-125136
Published: 2019